2015
DOI: 10.1038/leu.2015.103
|View full text |Cite
|
Sign up to set email alerts
|

Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy

Abstract: Sézary syndrome (SéS) represents a leukemic variant of cutaneous T-cell lymphoma, whose etiology is still unknown. To identify dyregulated genes in SéS, we performed transcriptional profiling of Sézary cells (SCs) obtained from peripheral blood of patients with SéS. We identified versican as the highest upregulated gene in SCs. VCAN is an extracellular matrix proteoglycan, which is known to interfere with different cellular processes in cancer. Versican isoform V1 was the most commonly upregulated isoform in S… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
23
0
1

Year Published

2017
2017
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(24 citation statements)
references
References 49 publications
0
23
0
1
Order By: Relevance
“…PI3K/mTOR as a therapeutic target in CTCL Another benefit of treating CTCL patients with PI3K/mTOR inhibitors could arise from the ability of PF-502 to abrogate tumor cell migration toward SDF-1. This chemokine is particularly abundant in the skin of SS patients owing to several mechanisms, such as the lack of the CD26 peptidase on the SS cell surface, inactivating SDF-1 (Narducci et al, 2006) and the overexpression of versican proteoglycan enhancing locomotion (Fujii et al, 2015). Moreover, we recently described the loss of the b-arrestin-2 gene in about 60% of SS cases, causing a defect in the CXCR4 internalization (Cristofoletti et al, 2019a).…”
Section: Discussionmentioning
confidence: 99%
“…PI3K/mTOR as a therapeutic target in CTCL Another benefit of treating CTCL patients with PI3K/mTOR inhibitors could arise from the ability of PF-502 to abrogate tumor cell migration toward SDF-1. This chemokine is particularly abundant in the skin of SS patients owing to several mechanisms, such as the lack of the CD26 peptidase on the SS cell surface, inactivating SDF-1 (Narducci et al, 2006) and the overexpression of versican proteoglycan enhancing locomotion (Fujii et al, 2015). Moreover, we recently described the loss of the b-arrestin-2 gene in about 60% of SS cases, causing a defect in the CXCR4 internalization (Cristofoletti et al, 2019a).…”
Section: Discussionmentioning
confidence: 99%
“…Since SS cells do not express SDF-1 mRNA, but rather they seem to uptake the SDF-1 released from epithelial, dendritic and endothelial cells of the skin [23], we can speculate that SS cells move toward skin through a chemotactic gradient [23]. This hypothesis is further reinforced by the lack from SS cell surface of CD26 peptidase able to cleave and inactivate SDF-1 [23], by the versican overexpression, a proteoglycan that enhances the SS locomotion toward SDF-1 [45] and by the comparable levels of plasmatic SDF-1 found between HDs and SS individuals ( data not shown ).…”
Section: Discussionmentioning
confidence: 99%
“…In addition, versican was identified as one of the most upregulated genes in lymphocytes isolated from patients with Sezary syndrome which is a leukemic variant of cutaneous T cell lymphoma. In this setting, versican promoted the invasive and homing capacity of the lymphocytes from these patients (148). Interestingly, the cleavage of versican by ADAMTS enzymes is critical for T-cell trafficking in mouse models of influenza virus infection (149).…”
Section: Versican: Interplay With Leukocytesmentioning
confidence: 99%